• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    2/5/25 5:13:36 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDMO alert in real time by email
    S-8 POS 1 ef20042918_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on February 5, 2025
     
    Registration No. 333-164026
    Registration No. 333-171067
    Registration No. 333-178452
    Registration No. 333-185423
    Registration No. 333-192794
    Registration No. 333-208466
    Registration No. 333-215053
    Registration No. 333-228735
    Registration No. 333-265905
    Registration No. 333-274399


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    Post-Effective Amendment No 1.
    To:



    Form S-8 Registration Statement No. 333-164026
    Form S-8 Registration Statement No. 333-171067
    Form S-8 Registration Statement No. 333-178452
    Form S-8 Registration Statement No. 333-185423
    Form S-8 Registration Statement No. 333-192794
    Form S-8 Registration Statement No. 333-208466
    Form S-8 Registration Statement No. 333-215053
    Form S-8 Registration Statement No. 333-228735
    Form S-8 Registration Statement No. 333-265905
    Form S-8 Registration Statement No. 333-274399



    UNDER
    THE SECURITIES ACT OF 1933



    AVID BIOSERVICES, INC.
    (Exact name of Registrant as Specified in Its Charter)



    Delaware
     
    95-3698422
    (State or other jurisdiction of Incorporation or organization)
     
    (I.R.S. Employer Identification No.)

    14191 Myford Road
    Tustin, CA 92780
    (Address of Principal Executive Offices)



    Peregrine Pharmaceuticals, Inc. 2009 Stock Incentive Plan
    Peregrine Pharmaceuticals, Inc. 2010 Stock Incentive Plan
    Peregrine Pharmaceuticals, Inc. 2010 Employee Stock Purchase Plan
    Peregrine Pharmaceuticals, Inc. 2011 Stock Incentive Plan
    Avid Bioservices, Inc. 2018 Omnibus Incentive Plan
    Avid Bioservices, Inc. Deferred Compensation Plan
    (Full titles of the plans)



    Mark R. Ziebell
    Vice President, General Counsel and Corporate Secretary
    14191 Myford Road
    Tustin, California 92780
    (714) 508-6100

    (Name, address and telephone number, including area code, of agent for service)



    Copy to:

    Zachary Blume
    Ropes & Gray LLP
    800 Boylston St
    Boston, Massachuetts, 02199
    (617) 951 7663

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☒
           
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
           
       
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐



     DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 relates to the following Registration Statements on Form S-8 (each, a “Registration Statement” and collectively, the “Registration Statements”) of Avid Bioservices, Inc., a Delaware corporation (the “Registrant” or the “Company”), which were previously filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”) and is being filed to deregister any and all securities that remain unsold or otherwise unissued as of the date hereof under each such Registration Statement:


    •
    Registration File No. 333-164026, filed with the SEC on December 24, 2009, registering 3,000,000 shares of the Registrant’s common stock, par value $0.001 (“Common Stock”) issuable under the Peregrine Pharmaceuticals, Inc. 2009 Stock Incentive Plan (the “2009 Stock Incentive Plan”);


    •
    Registration File No. 333-171067, filed with the SEC on December 9, 2010, registering 3,500,000 shares of Common Stock issuable under the Peregrine Pharmaceuticals, Inc. 2010 Stock Incentive Plan (the “2010 Stock Incentive Plan”), and 5,000,000 shares of Common Stock issuable under the Peregrine Pharmaceuticals, Inc. 2010 Employee Stock Purchase Plan (the “2010 Stock Purchase Plan”);


    •
    Registration File No. 333-178452, filed with the SEC on December 12, 2011, registering 3,500,000 shares of Common Stock issuable under the Peregrine Pharmaceuticals, Inc. 2011 Stock Incentive Plan (the “2011 Stock Incentive Plan”);


    •
    Registration File No. 333-185423, filed with the SEC on December 12, 2012, registering 8,000,000 shares of Common Stock issuable under the 2011 Stock Incentive Plan;


    •
    Registration File No. 333-192794, filed with the SEC on December 12, 2013, registering 7,000,000 shares of Common Stock issuable under the 2011 Stock Incentive Plan;


    •
    Registration File No. 333-208466, filed with the SEC on December 10, 2015, registering 15,000,000 shares of Common Stock issuable under the 2011 Stock Incentive Plan;


    •
    Registration File No. 333-215053, filed with the SEC on December 12, 2016, registering 10,000,000 shares of Common Stock issuable under the 2010 Stock Purchase Plan;


    •
    Registration File No. 333-228735, filed with the SEC on December 10, 2018, registering (i) 7,152,404 shares of Common Stock issuable under the Avid Bioservices, Inc. 2018 Omnibus Incentive Plan (the “2018 Incentive Plan”), which includes 2,350,000 shares of Common Stock initially available for awards under the 2018 Incentive Plan, plus 1,892,100 shares of Common Stock previously reserved but unissued and not subject to outstanding awards under the 2009 Stock Incentive Plan, 2010 Stock Incentive Plan and 2011 Stock Incentive Plan (the “Prior Plans”), plus 3,009,824 shares of Common Stock reserved but unissued and subject to outstanding awards under the Prior Plans, less 99,520 shares of Common Stock underlying stock options granted pursuant to the 2018 Incentive Plan and (ii) 99,520 shares of Common Stock subject to outstanding stock option awards previously granted under the 2018 Incentive Plan;


    •
    Registration File No. 333-265905, filed with the SEC on June 29, 2022, registering 3,400,000 shares of Common Stock issuable under the 2018 Omnibus Incentive Plan; and


    •
    Registration File No. 333-274399, filed with the SEC on September 7, 2023, registering the obligations of the Company to make future payments to participants in  the Company’s Deferred Compensation Plan (the “Deferred Compensation Plan”).

    On February 5, 2025, pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024, by and among the Company, Space Finco, Inc. (“Parent”) and Space Mergerco, Inc. (“Merger Sub”), Merger Sub merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation of the Merger and a wholly owned subsidiary of Parent.


    As a result of the Merger, the Registrant has terminated any and all offerings of the Registrant’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tustin, State of California, on February 5, 2025.
     
     
    AVID BIOSERVICES, INC.
       
     
    By:
     /s/ Daniel R. Hart
       
    Daniel R. Hart
        Chief Financial Officer

    No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933, as amended.
     


    Get the next $CDMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDMO

    DatePrice TargetRatingAnalyst
    9/28/2023Mkt Perform
    William Blair
    3/14/2023$20.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/9/2022$31.00 → $28.00Overweight
    Stephens & Co.
    12/8/2021$29.00 → $35.00Buy
    Craig-Hallum
    12/8/2021$27.00 → $32.00Outperform
    RBC Capital
    12/8/2021Overweight → Sector Weight
    Keybanc
    6/30/2021$21.00 → $29.00Buy
    Craig-Hallum
    6/30/2021$21.00 → $27.00Outperform
    RBC Capital
    More analyst ratings

    $CDMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

      TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers. The reimagined Avid website captures the company's elevated brand throu

      2/10/25 8:05:59 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

      TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the "Notice") to holders of its 7.00% Convertible Senior Notes due 2029 (the "Notes"), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the "Indenture"), by and between the Company and U.S. Bank Trust Company, National Association ("U.S. Bank"), as trustee, governing the Notes that, in connection with the closing of the transa

      2/5/25 10:45:00 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

      Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners ("Ampersand"), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices

      2/5/25 9:55:00 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      1/10/24 7:56:02 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      12/18/23 7:31:12 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      9/22/23 12:51:46 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Avid Bioservices Inc.

      15-12G - Avid Bioservices, Inc. (0000704562) (Filer)

      2/18/25 6:07:47 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Avid Bioservices Inc.

      S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

      2/5/25 5:13:38 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Avid Bioservices Inc.

      S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

      2/5/25 5:13:36 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      2/7/25 7:40:25 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      2/7/25 7:40:10 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      2/7/25 7:39:57 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Financials

    Live finance-specific insights

    See more
    • Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024

      TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024. Highlights from the Quarter Ended October 31, 2024: "We delivered solid results in a competitive environment, with increased revenues and backlog offset by increased costs," stated Nick Green, president and CEO of Avid Bioservices. "We are pleased to reach the separately announced agre

      12/10/24 4:05:23 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

      -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:

      9/9/24 4:05:31 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

      TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please

      9/3/24 4:05:20 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Avid Bioservices

      William Blair initiated coverage of Avid Bioservices with a rating of Mkt Perform

      9/28/23 8:08:44 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Avid Bioservices from Sector Weight to Overweight and set a new price target of $20.00

      3/14/23 7:17:41 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

      Stephens & Co. reiterated coverage of Avid Bioservices with a rating of Overweight and set a new price target of $28.00 from $31.00 previously

      3/9/22 6:57:34 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/1/23 6:16:00 PM ET
      $ALK
      $ALKS
      $AWI
      $BLDR
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Avid Bioservices Appoints Oksana Lukash as Vice President, People

      TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year

      11/16/22 8:05:00 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avid Bioservices Inc.

      SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

      12/13/24 10:53:25 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

      SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

      11/14/24 7:53:01 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

      SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

      11/12/24 4:15:31 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care